Avenue Therapeutics (NASDAQ:ATXI) Stock Price Up 4.7% – Time to Buy?

Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) shares traded up 4.7% during trading on Tuesday . The stock traded as high as $0.5382 and last traded at $0.50. Approximately 4,912 shares changed hands during trading, a decline of 28% from the average session volume of 6,836 shares. The stock had previously closed at $0.4776.

Avenue Therapeutics Price Performance

The firm has a market cap of $1.65 million, a P/E ratio of 0.03 and a beta of -0.18. The business’s 50-day moving average is $0.40 and its two-hundred day moving average is $0.37.

Avenue Therapeutics Company Profile

(Get Free Report)

Avenue Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for acute pain and other central nervous system conditions. The company is a subsidiary of Fortress Biotech, Inc and has historically concentrated its efforts on hospital-based treatments that address unmet medical needs.

Avenue’s lead product candidate is an intravenous formulation of tramadol intended to manage acute postoperative pain in adults who require an opioid analgesic.

Further Reading

• Five stocks we like better than Avenue Therapeutics
• Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
• Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
• AMD Chips Away at NVIDIA’s AI Throne
• Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?